Business Description
Knight Therapeutics Inc
NAICS : 325410
SIC : 3741
ISIN : CA4990531069
Total Employee Number:
830Compare
Compare
Traded in other countries / regions
GUD.CanadaKHTRF.USA04K.Germany IPO Date
2014-05-05Description
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.05 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | 0.87 | |||||
Interest Coverage | 1.22 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.97 | |||||
Beneish M-Score | -2.7 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 20.9 | |||||
3-Year EBITDA Growth Rate | 40.2 | |||||
3-Year EPS without NRI Growth Rate | -8.1 | |||||
3-Year FCF Growth Rate | 28.5 | |||||
3-Year Book Growth Rate | 1.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 6.66 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 92.73 | |||||
9-Day RSI | 84.45 | |||||
14-Day RSI | 78.49 | |||||
3-1 Month Momentum % | 10.26 | |||||
6-1 Month Momentum % | 34.31 | |||||
12-1 Month Momentum % | 35.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.32 | |||||
Quick Ratio | 1.59 | |||||
Cash Ratio | 0.74 | |||||
Days Inventory | 188.07 | |||||
Days Sales Outstanding | 85.91 | |||||
Days Payable | 159.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 4 | |||||
Shareholder Yield % | -2.41 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 45.93 | |||||
Operating Margin % | 2.7 | |||||
Net Margin % | 1.1 | |||||
EBITDA Margin % | 15.74 | |||||
FCF Margin % | 13.39 | |||||
OCF Margin % | 20.8 | |||||
ROE % | 0.72 | |||||
ROA % | 0.54 | |||||
ROIC % | 1.25 | |||||
3-Year ROIIC % | 13.82 | |||||
ROC (Joel Greenblatt) % | 12.4 | |||||
ROCE % | 2.18 | |||||
Years of Profitability over Past 10-Year | 7 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 198.2 | |||||
Forward PE Ratio | 51.27 | |||||
PE Ratio without NRI | 152.46 | |||||
Shiller PE Ratio | 110.87 | |||||
Price-to-Owner-Earnings | 40.45 | |||||
PEG Ratio | 22.42 | |||||
PS Ratio | 1.93 | |||||
PB Ratio | 1.24 | |||||
Price-to-Tangible-Book | 2.88 | |||||
Price-to-Free-Cash-Flow | 14.34 | |||||
Price-to-Operating-Cash-Flow | 9.29 | |||||
EV-to-EBIT | 46.89 | |||||
EV-to-EBITDA | 11.19 | |||||
EV-to-Revenue | 1.76 | |||||
EV-to-Forward-Revenue | 1.72 | |||||
EV-to-FCF | 13.13 | |||||
Price-to-GF-Value | 1.15 | |||||
Price-to-Projected-FCF | 2.48 | |||||
Price-to-Median-PS-Value | 0.56 | |||||
Price-to-Peter-Lynch-Fair-Value | 18.91 | |||||
Price-to-Graham-Number | 4.42 | |||||
| Price-to-Net-Current-Asset-Value | 6.58 | |||||
Earnings Yield (Greenblatt) % | 2.13 | |||||
FCF Yield % | 7.04 | |||||
Forward Rate of Return (Yacktman) % | 7.44 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Knight Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 318.945 | ||
| EPS (TTM) (€) | 0.031 | ||
| Beta | 0.0482 | ||
| 3-Year Sharpe Ratio | 0.87 | ||
| 3-Year Sortino Ratio | 2.11 | ||
| Volatility % | 27.96 | ||
| 14-Day RSI | 78.49 | ||
| 14-Day ATR (€) | 0.055097 | ||
| 20-Day SMA (€) | 5.7775 | ||
| 12-1 Month Momentum % | 35.03 | ||
| 52-Week Range (€) | 3.46 - 6.05 | ||
| Shares Outstanding (Mil) | 98.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Knight Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Knight Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 08:30 | In 123 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 122 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 08:30 | In 32 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 31 days | ||
| Guidance call for 2026 | 2026-06-04 14:35 | 5.05 (+0.00%) | ||
| Guidance call for 2026 | 2026-05-19 09:00 | 5.25 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:30 | 4.72 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 4.72 (+0.00%) | ||
| General meeting for 2026 | 2026-05-06 09:00 | 4.74 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-19 08:30 | 3.88 (+0.00%) |
Show
Entries
Knight Therapeutics Inc Frequently Asked Questions
What is Knight Therapeutics Inc(FRA:04K)'s stock price today?
The current price of FRA:04K is €6.05. The 52 week high of FRA:04K is €6.05 and 52 week low is €3.46.
When is next earnings date of Knight Therapeutics Inc(FRA:04K)?
The next earnings date of Knight Therapeutics Inc(FRA:04K) is 2026-08-07 Est..
Does Knight Therapeutics Inc(FRA:04K) pay dividends? If so, how much?
Knight Therapeutics Inc(FRA:04K) does not pay dividend.
Press Release
Articles on Knight Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers